Whether you love it or hate it, BMI is making headlines again, igniting discussions on how to accurately define obesity.
The weight-to-height-squared formula, known as BMI or body mass index, has faced criticism for being an overly simplistic measure of obesity. This metric can mistakenly categorize people with high muscle mass as obese, just like those with excess fat, while overlooking differences among populations. More than a year ago, a global commission from Lancet Diabetes and Endocrinology challenged the reliance on BMI. They advocated for broader use of measures like waist circumference, waist-to-hip ratio, and waist-to-height ratio, which are gaining consensus.
The commission introduced a novel approach by distinguishing between preclinical and clinical obesity, aiming for more precise diagnoses starting with BMI and other body fat indicators. Individuals with preclinical obesity may have excess body fat and an increased risk of developing cardiovascular issues, type 2 diabetes, certain cancers, or other organ dysfunctions, but remain undiagnosed. In contrast, those with clinical obesity have already manifested a related illness.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
